Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.
"We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case presentation at the prestigious HRS meeting," said Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences. "The preclinical and initial clinical outcomes from studies with our surgical clamp and catheter are encouraging and we continue to believe that CellFX nsPFA can meaningfully advance the treatment of atrial fibrillation."
Posted In: PLSE